U.S. markets open in 2 hours 1 minute

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1570-0.0060 (-3.68%)
At close: 3:24PM EST
Sign in to post a message.
  • M
    Mark
    Man, this has been a LONG hold. I showed this to my brother who is a doctor about two years ago and he said, well, if they can sell it, it looks good. Let's see.
  • O
    OGF
    The ask of around 500K shares that triggered the price waterfall yesterday was never filled and then was removed and didn't come back today. Maybe someone triggered the price to fall to accumulate more?
  • T
    Tux
    Looks like a lot of people wanted out at .20
    Neutral
  • M
    M
    Innovative and top of the line products now with a solid global distribution agreement! This will go through the roof if it starts to trend.
  • T
    Teddy
    How did you think a company valued at 40million with its headquarters in a tiny rental unit in the middle of nowhere making a product that nobody bought by someone that nobody heard of was going to go anywhere? Please wake up !
  • T
    Tommy
    Arch went up a penny.!! Ring out the Church Bells..! Strike up the Band..!!
  • D
    Done
    Well @Bal and @Sundflower finally have their partnership deal (Whatever happened to @Joey?). Welcome to the real world where investors look to sales performance in order to value the shares.
  • T
    Teddy
    Telling lots of people there are investors hoping to cash out when the share price rises will hardly encourage inward investment!
  • D
    Done
    T.N.'s feet will be to the fire next week when he has to tell the Wainright conference what his sales expectorations are!
  • S
    Steven
    Could’ve tax loss harvesting for the year. Thoughts?
  • D
    Done
    Archie slipped its Annual Report on Form 10K under the door last night. Read it and weep...
  • H
    Harry
    Hi Done, it's been a couple of years. It looks like the gifted six have probably milked this one for all it's worth. They probably have a new startup somewhere they are stealing money from now. It wouldn't matter if they got any of their things approved now anyway. The wound care market has developed other solutions and moved on. In case you don't remember me Bal this is bird brain Terry. How stupid do all those posts I made a few years ago about this company being a rip off look now.
  • s
    sukumaran
    I think the company is going to be sold or get a strategic investor in the very near future.
  • D
    Done
    That ten minutes of Blah Blah Blah sure had an effect, eh?
  • D
    Done
    Volume is supremely low, but it is astonishing that anyone at all would actually pay up and buy a single share to Archie at this point in time. The company is on the ropes, cash-strapped, and out of compliance with SEC reporting requirements. And not even a submission from the company asking the SEC for forbearance? It is almost Thanksgiving and this turkey is near done.
  • D
    Done
    The Parkers come to the rescue! They lend Archie $1,050,000 (Archie's P/R rounds up to $1.1M) at 10% per annum for three years. Just to make it interesting, and to get @bal and @Sunflower excited, the note is convertible at a value of 25-cents per share, so long as the share price breaks 32-cents. That $1-M will last Archie about three months. What's he do after that? Clearly, the proposed equity raise is going nowhere.
  • D
    Done
    Due today is Archie's 10Q for the recently completed quarter. Will his CFO get it in today, or will we see an extension filed? Will Archie slip it in under the door without a P/R announcing it again?
  • b
    bal
    Good news this morning to see fda approved of Arch pre submission plan or else this woulda been a fire sale for whatever they could get. Now we are meekly back on track. Arch needs to get this study done in the required time they set out and have a re-submission early Q3 to avoid the need of dilution before an fda approval. Would also be nice if CE could be dual filed with the 510k in Q3 but I'm not holding my breadth. If the study results come back strong I will add more to my position. For now I wouldn't buy, and am not selling any of my shares. Good luck to all.
  • S
    SundanceKid
    The truth about ARTH!!! (From an extremely knowledgeable source!)

    This post is long so it is spread out in the comments (follow numbered comments for order.)

    I had a very interesting conversation yesterday that I would really like to tell you all about.

    Let me first say that I bought into ARTH just about a month prior to the unpredicted withdrawal of their FDA submission last year. I was geared up for a quick turnover hoping to sell all those shares for a massive gain in a matter of a couple of months. Obviously that did not happen.

    Like many investors I became frustrated with what has been happening with this company. I started reading posts online that portrayed this stock as a serial pump-and-dump scheme run by a disreputable and self-interested management team. Having a sizable portion of my portfolio vested in this company, obviously I had some significant worries.

    Well, I reached out to the company recently to share my concerns, but did not expect this particular response. You see, yesterday I received a call back from Terrence Norchi (CEO) and Richard Davis (CFO.) They had read my email and decided to make the time (over an hour of their time actually) to speak with me about who they are, what they are doing, and where they hope their vision will carry this company. Obviously they did not share anything with me that is outside the realm of the public domain. But what they did share with me that I did not receive previously from Norchi’s numerous public appearances, was the sense of genuine dedication that he and his team have to the development of a truly innovative line of products rooted in their exclusive IP rights.

    Let me start by saying that they are not running a financial scheme to make us all rich overnight. We might be upset that the stock has yet to soar, and truthfully, they too have been a bit disappointed in the general stock’s performance following the FDA approval. But they are not managing a stock. They are managing a pharmaceutical company that holds the exclusive IP for some very exciting and innovative technology that Terrance Norchi and his company genuinely believe in.
    Mr. Norchi’s faith in the line of potential products he hopes to see emerge from this endeavor is evident in the years of work and dedication he has already poured into building Arch as a company, as well as the fact that unlike us that hold diversified portfolios, Norchi himself is fully and solely invested into ARTH. As an entrepreneur and a family man, he has the most to lose being that he is the largest share holder in the company.
  • J
    Joseph
    Today’s press release, notable comment: “We are also pleased that the study remains on budget, and we now anticipate that our corporate cash runway has extended into the fourth calendar quarter of 2018.”